Headlines about Kalvista Pharmaceuticals (NASDAQ:KALV) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Kalvista Pharmaceuticals earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news coverage about the specialty pharmaceutical company an impact score of 46.8731339513815 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

A number of equities research analysts have commented on KALV shares. ValuEngine upgraded Kalvista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Roth Capital started coverage on Kalvista Pharmaceuticals in a research report on Tuesday, July 10th. They issued a “buy” rating and a $20.00 target price on the stock. BTIG Research restated a “buy” rating on shares of Kalvista Pharmaceuticals in a research report on Sunday, April 29th. Finally, TheStreet downgraded Kalvista Pharmaceuticals from a “c-” rating to a “d+” rating in a research report on Wednesday, May 2nd.

NASDAQ:KALV traded up $0.08 on Friday, reaching $13.05. The company’s stock had a trading volume of 400 shares, compared to its average volume of 30,232. Kalvista Pharmaceuticals has a 12-month low of $5.48 and a 12-month high of $15.80. The company has a market capitalization of $134.35 million, a P/E ratio of -8.53 and a beta of 2.53.

Kalvista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Tuesday, July 31st. The specialty pharmaceutical company reported ($0.06) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.29. Kalvista Pharmaceuticals had a negative return on equity of 55.65% and a negative net margin of 188.29%. The company had revenue of $4.84 million for the quarter. equities analysts expect that Kalvista Pharmaceuticals will post -0.93 EPS for the current year.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

See Also: Growth Stocks

Insider Buying and Selling by Quarter for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.